-
Morgan Stanley: Illumina's Q1 Guidance Puts 2019 Targets In Question
Wednesday, January 30, 2019 - 11:58am | 339Read More...Illumina, Inc. (NASDAQ: ILMN) announced 2019 revenue growth guidance of 13-14 percent, and much of this revenue growth is expected to be in the back half of the year. Yet the company's first-quarter guidance raises concerns around whether Illumina can meet its full-year target, according...
-
Market, Policy Trends Are Shifting In Illumina's Favor, Morgan Stanley Says In Upgrade
Tuesday, August 7, 2018 - 11:43am | 397Read More...The bearish case for Illumina, Inc. (NASDAQ: ILMN) has come to an end for four key reasons, according to Morgan Stanley. The Analyst Analyst Steve Beuchaw upgraded Illumina from Underweight to Equal-weight with a price target lifted from $210 to $320. The Thesis Illumina stands to benefit from...
-
4 Reasons Why Morgan Stanley Is Bullish On Myriad Genetics
Wednesday, July 11, 2018 - 2:15pm | 475Read More...Shares of molecular diagnostic company Myriad Genetics, Inc. (NASDAQ: MYGN) have 45-percent upside potential, according to Morgan Stanley. The Analyst Analyst Steve Beuchaw upgraded shares of Myriad Genetics from Equal-weight to Overweight and increased the price target from $35 to $55....
-
Align Tech Faces Slowing Growth, Potential Headwinds, Morgan Stanley Says In Downgrade
Thursday, April 19, 2018 - 12:00pm | 383Read More...Orthodontic supplier Align Technology, Inc. (NASDAQ: ALGN)'s long-term potential is likely to be overshadowed by slowing growth in the near term and a "demanding" multiple, according to Morgan Stanley. The Analyst Analyst Steve Beuchaw downgraded shares of Align Technology...
-
Henry Schein, Patterson Companies Downgraded On Amazon Fears
Wednesday, December 6, 2017 - 10:39am | 444Read More...Online retailer Amazon.com, Inc. (NASDAQ: AMZN) and its aggressive expansion has put many retailers in a tight spot. Most recently, an analyst expressed concerns about its challenge to dental supplies and equipment distribution companies Henry Schein, Inc. (NASDAQ: HSIC) and Patterson Companies...
-
Dentsply Sirona Is At An Attractive Entry Point For Investors Seeking Play On Structural Growth In Med-Tech
Tuesday, November 1, 2016 - 11:00am | 297Read More...Following the 10 percent decline in Dentsply Sirona Inc (NASDAQ: XRAY) shares, compared to the 7 percent rise in the broader MedTech, Morgan Stanley’s Steve Beuchaw believes investors now have an attractive entry point into a “structural growth story.” Beuchaw upgraded the...
-
Even After Dipping Under $21, Morgan Stanley Says Myriad Genetics Is Not Cheap
Wednesday, August 10, 2016 - 10:07am | 318Read More...Shares of Myriad Genetics, Inc. (NASDAQ: MYGN) were trading lower by nearly 30 percent Wednesday at $21.49 after the company's fiscal fourth quarter earnings print fell short of expectations and its forward looking guidance also fell short of what the Street was expecting. Steve...
-
Morgan Stanley Sees Illumina Trading At Too High A Premium To Its Peers
Tuesday, July 5, 2016 - 11:14am | 273Read More...Morgan Stanley’s Steve Beuchaw prefers to take cautious stance on Illumina, Inc. (NASDAQ: ILMN), following new data on targeted cancer drug trends, as well as checks in the clinical lab space. Beuchaw downgraded the rating on the company to Underweight, while lowering the price target from $...
-
Cepheid Margin Expansion Unlikely To Morgan Stanley, Stays On Sidelines
Wednesday, June 15, 2016 - 4:12pm | 382Read More...Morgan Stanley's Steve Beuchaw initiated Cepheid (NASDAQ: CPHD) at Equal-Weight with a $30.00 price target. Beuchaw was especially worried about low margin expectations and future extensive spending. "CPHD is a share gainer in a healthy molecular diagnostics market, but we see limited upside to...
-
Agilent's FY17 Outlook Weaker Than Expected, But Looks Beatable, Morgan Stanley Says
Tuesday, May 17, 2016 - 9:24am | 317Read More...Agilent Technologies Inc (NYSE: A) reported its 2FQ16 results ahead of expectations. Morgan Stanley’s Steve Beuchaw maintained an Equal-Weight rating for the company, while raising the price target from $44 to $47. The analyst commented that although the initial FY17 guidance was weaker...
-
Morgan Stanley Downgrades Dentsply, Says 'Time For A Breather'
Thursday, March 24, 2016 - 8:26am | 295Read More...Morgan Stanley’s Steve Beuchaw downgraded the rating on DENTSPLY SIRONA Inc (NASDAQ: XRAY) to Equal-weight, with a price target of $65. While expressing optimism regarding the Dentsply-Sirona synergies, Beuchaw provided a word of caution regarding the underlying growth outlook and...
-
A Dentist's Pair Trade: Buy Dentsply, Sell Sirona Dental
Monday, September 14, 2015 - 12:32pm | 506Read More...DENTSPLY International Inc (NASDAQ: XRAY) shares have been on a downtrend, after touching a high of $57.29 on August 12. Sirona Dental Systems, Inc. (NASDAQ: SIRO) shares are down 3.73 percent since August 18. Morgan Stanley’s Steve Beuchaw upgraded the rating on DENTSPLY to Overweight...
-
Morgan Stanley Neutral On Natera, Starts At Equal-Weight
Monday, July 27, 2015 - 10:15am | 273Read More...In a report published Monday, Morgan Stanley analyst Steve Beuchaw initiated coverage of Natera Inc (NASDAQ: NTRA) with an Equal-weight rating and price target of $20. The analyst expects the company to grow at a CAGR of 25 percent over the next three years into a TAM worth $15 billion,...
-
Morgan Stanley Reiterates Overweight, Raises PT On NanoString Technologies On Increased Visibility
Tuesday, March 24, 2015 - 8:23am | 134Read More...In a report published Tuesday, Morgan Stanley analyst Steve Beuchaw reiterated an Overweight rating on NanoString Technologies Inc. (NASDAQ: NSTG), and raised the price target from $16.00 to $17.00. In the report, Morgan Stanley noted, "The company's success in the biopharma space remains...
-
Morgan Stanley Reiterates Equal-Weight, Lowers PT On Veracyte As Expectations Are Now Better Calibrated
Friday, March 20, 2015 - 9:25am | 83Read More...In a report published Friday, Morgan Stanley analyst Steve Beuchaw reiterated an Equal-Weight rating on Veracyte Inc. (NASDAQ: VCYT), but lowered the price target from $10.00 to $9.00. In the report, Morgan Stanley noted, "Despite lower guidance and a higher share count, shares remain inexpensive...
